Prostat kanseri hastalarinda epidermal büyüme faktörü reseptörü polimorfizminin incelenmesi

Cancer is associated with increased mortality ratio worldvide while, prostate cancer (PC), possess the most prevalent death ratio among male population. The metastatic form of PC is the second leading cause of cancer-related death. Epidermal Growth Factor (EGF) receptor (EGFR), is one of a member of ErbB family of receptor tyrosine kinases (RTKs) that encodes 170 kD glycoprotein. Studies have revealed that single nucleotide polymorphisms (SNPs) occurring in the EGFR gene cause different types of carcinomas, such as prostate adenocarcinomas and gliomas [1]. For better understanding of how EGFR polymorphism lead to cancer development, case-control study has been conducted in Turkish male population with 61 patient and 62 healty individuals. Genotype analysis was performed with Real-Time PCR method for both patient and control groups and statistical data were obtained from SPSS. Based on the eveluated results, CC homozygous genotype 24 (38.7%), CT heterozygous genotype 53.2(%33), TT homozygous genotype 5 (8.1%) has been detected in patient group. On the other hand, CC genotype 30 (49.2%), CT genotype 26 (42.6%) and TT genotype 5 (8.2%) has been recorded in control group. Consequently, there is a non-significant association between patient and control groups depend on genotype analysis (p=0.475). This study aims to detect EGFR rs1468727 SNP in patient with prostate cancer is Turkish population and improve new aspects to clinical trials. Key words: Cancer, prostate cancer, EGFR